The cGMP-binding cGMP-specific phosphodiesterase (PDE5) contains a catalytic domain that hydrolyzes cGMP and a regulatory (R) domain that contains two GAFs (a and b), binds cGMP allosterically, provides for dimerization, and is phosphorylated at a site regulated by allosteric cGMP binding. 
Intracellular levels of cyclic nucleotides (cNs) are largely determined by the balance between the rates of synthesis by adenylyl or guanylyl cyclases and breakdown by cN phosphodiesterases (PDEs) (1-7). PDE catalytic activities provide the main mechanism for lowering intracellular cN levels (7) (8) (9) (10) (11) (12) . All known mammalian PDEs are Class I PDEs that have been divided into 11 families based on biochemical properties, DNA sequence analyses, and pharmacological characteristics. All are chimeric proteins comprised of a catalytic domain (C domain) and a regulatory domain (R domain). R domains of mammalian PDEs 2, 5, 6, 10, and 11 contain either one or two predicted homologous GAF modules of ~120 AA (12) (13) (14) . The GAF acronym is derived from the names of the first three classes of proteins recognized to contain this module: mammalian cGMP-binding PDEs, Anabaena adenylyl cyclases, and Escherichia coli (FhlA) (15) . GAFs are one of the largest families of protein modules and are closely related to PAS domains (found in period clock protein, aryl hydrocarbon receptor and single-minded protein). However, little is known about GAF functions or the physical features that provide for their stability and function. GAFs are commonly described as ligand-binding domains, but such a function has been demonstrated for only a few (16) (17) (18) (19) (20) (21) (22) (23) .
The PDE superfamily is the only group of mammalian proteins known to have an abundance of GAFs (17) ; all isoforms of four PDE families (PDEs 2, 5, 6, and 10) contain two GAFs (a and b) arranged in tandem, and in PDEs 2, 5, and 6, at least one GAF forms an allosteric site for cGMP binding (14, 22, (24) (25) (26) . Even among cGMP-binding PDEs, the functions of the respective GAFs are not conserved. Many questions remain regarding the structure-function relationships within the R domains of these PDEs, the roles of GAFs a and b in function, and the physical parameters that provide for cGMP-binding and regulation of function by post-translational modifications such as phosphorylation (14, 16, 22, 27) .
Cyclic GMP-binding, cGMP-specific phosphodiesterase (PDE5), which is the focus of this study, plays a prominent role in cGMP breakdown in lung, platelets, gastrointestinal epithelial cells, Purkinje cells of the cerebellum, and vascular smooth muscle (12, 28, 29) . PDE5 is the target of sildenafil (Viagra™), tadalafil (Cialis™), and vardenafil (Levitra™), all of which are in use for treatment of maladies associated with vascular disease (30) (31) (32) (33) (34) (35) (36) (37) . Each monomer within PDE5 R domain contains a site for phosphorylation whose solvent exposure is modulated by allosteric cGMP binding, two potential sites for allosteric cGMPbinding (GAFs a and b), and a dimerization interface. Partial proteolysis of PDE5 (subunit M r ~ 100 kDa) generates a stable dimeric cGMP-binding fragment with subunits of ~ 45 kDa (38) suggesting strong dimerization interactions within or near the GAFs since the isolated C domain is monomeric (39) (40) (41) . While some GAFs form dimers, others apparently do not (14, 42) . Allosteric cGMP-binding to the R domain stimulates phosphorylation of human PDE5 (hPDE5) at Ser 102 by either PKG or the isolated catalytic subunit (C subunit) of PKA (27, 38, 43, 44) . The phosphorylation increases the cGMP-binding affinity of the allosteric sites in the R domain, converts a kinetically heterogeneous population of binding sites to a single kinetic species, and concomitantly increases catalytic activity. The molecular events that provide for this cGMP regulation of Ser 102 phosphorylation and the associated increase in allosteric cGMP-binding affinity occur within the context of the R domain (27) . Cyclic GMP binding to the allosteric sites also causes an apparent elongation of the enzyme (27, 45) and increases the affinity of the PDE5 C domain for substrate and inhibitors even in the absence of phosphorylation (43, (46) (47) (48) (49) (50) . Therefore, regulation of the autoinhibition/activation of PDE5 catalytic function by allosteric cGMP binding and/or phosphorylation involves interactions among multiple subdomains within the R domain.
Much evidence supports the interpretation that the effects of allosteric cGMP binding and/or phosphorylation to stimulate PDE5 catalytic activity is critically involved in negative feedback regulation of cellular cGMP levels; the same mechanisms also participate in a feed-forward feedback process to increase potency of PDE5 inhibitors (43, 50, 51) . However, mechanisms by which cGMP binding and phosphorylation of the R domain affect enzyme activity and the roles of individual GAFs in PDE5 are not fully understood.
To date, the physical boundaries that provide for cGMP binding have only been examined for GAF b in PDE2 (52) . In this report, the structural and functional features that provide for and modulate PDE5 R domain functions have been extensively defined and characterized by studying biochemical and biophysical properties of a collection of truncated mutants of recombinant His-tagged hPDE5A1; these include the holoenzyme, the fulllength and an N-terminally truncated PDE5A1 R domain containing both GAFs a and b and the phosphorylation site, and mutants containing either the isolated GAF a or b alone or with their respective flanking regions. These purified proteins have been characterized for cGMP-binding properties, quaternary structures, and cGMPmodulation of phosphorylation of Ser 102 . The results from each of these approaches establish functional features and mechanisms of regulation of PDE5 holoenzyme, expand knowledge of PDE structure/function relationships, and advance understanding of GAF domains.
Material and methods:
Construction of hPDE5A1 holoenzyme and isolated GAF mutants. Human cDNA coding for full-length PDE5A1 (courtesy of Dr. K. Omori, Tanabe-Seiyaku Pharmaceutical Co. Ltd., Saitama, Japan) was used as a template to generate the Histagged holoenzyme as well as a collection of ten His-tagged hPDE5A1 truncation mutants (mutant 1-10, depicted in Fig. 1A ). All constructs were created by introduction of start and stop codons at the appropriate loci. The resulting PCR fragment for each construct was cloned into pCR 2.1-TOPO vector (Invitrogen) and verified by sequencing, then excised by digestion with EcoRI and NotI and inserted into pAcHLT-A vector (Pharmingen) digested with the same enzymes. pAcHLT-A vector contains a His 6 sequence preceding the coding region, generating Nterminally His-tagged proteins. The boundaries for the GAF a and GAF b were selected based on homology with other GAF-containing PDEs (PDE2 and PDE6) since the precise boundaries of these functional modules were not known. Mutants included: the full-length R domain (mutant 1: M1-E539), an N-terminally truncated R domain containing both GAFs a and b and the phosphorylation site (mutant 2: V46-E539), a collection of constructs that contain the isolated GAF a and varying lengths of its respective flanking regions (mutant 3: M1-D403, mutant 4: M1-E321, mutant 5: V46-D403, mutant 6: V156-Q331 and mutant 7: V156-D403), an isolated GAF b construct containing the flanking regions on either side (mutant 8: T322-E539) and two constructs containing the GAF b conjoined with the C domain with (mutant 10: T322-N875) or without (mutant 9: E420-N875) the intervening sequence between GAFs a and b. Due to a low level of phosphate incorporation into Thr 50 (-Arg-Lys-Ala-Thr 50 -), which is located near the His-tag PDE5A1 junction in mutants 2 and 5, Thr 50 was mutated to alanine in these mutants using a QuikChange site-directed mutagenesis kit (Stratagene) and primer sets 5'-GAAAAGCCGCCAGAGAAATGGTCAATG-3' and 5'-CATTGACCATTTCTGGCGGCTTTTC-3'.
The following pairs of oligonucleotides containing EcoRI (underlined), NotI (italics) sites and a stop codon (boldface type) were used to generate the hPDE5A1 constructs: Met1f : 5'-GATATTGAATTCATGGAGCGGGCCGGCCCC  AGCT-3'  and  Glu539r:  5'-GATGATAGCGGCCGCCTACTCTCTTGTTTCT  TCCTCTGCT-3', for mutant 1; Val46f: 5'-GACATCGAATTCGTTAGAAAAGCCGCCAGA  GAAATGGT-3' and Glu539r, for mutant 2; Met1f  and  Asp403r:  5'-GTAGATAGCGGCCGCCTAATCATGTTCCCT  TGTTAATGTATC-3', for mutant 3; Met1f and  Glu321r:  5'-GTAGATAGCGGCCGCCTACTCATAGAGCTG  AGCATTATG, for mutant 4; Val46f and Asp403r  for  mutant  5;  Val156f:  5'-GACATCGAATTCGTGAAGGATATTTCTAGT  CA-3'  and  Gln331r  5'-GTAGATAGCGGCCGCCTACTGATTTCTCTTG   TTCTC-3' for mutant 6; Val156f and Asp403r for  mutant  7;  Thr322f,  5'-GACATCGAATTCACTTCACTGCTGGAGAAC  AAGAGA-3' and Glu539r for mutant 8; Glu420f:  5'-GACATCGAATTCGAACCACTTAATATCCCA  G-3'  and  Stop875r:  5'-GTGGACAGCGGCCGCTCAGTTCCGCTTGGC  CTGG-3', for mutant 9; Thr322f and Stop875r for  mutant 10, and Met1f and Stop875r for hPDE5A1 holoenzyme. An external PKA phosphorylation site (Arg-Arg-Ala-Ser-Val-Val), which was introduced by the baculovirus expression vector (pAcHLT-A) was removed by mutation of the Ser residue of this site to alanine in hPDE5 holoenzyme, mutant 1 (GAF a/b) and mutant 4 (GAF a) using a QuikChange site-directed mutagenesis kit (Stratagene) and primer sets 5'-GAAGGAGAAGGGCCGCTGTTGCGGCGGGA ATT-3' and 5'-AATTCCCGCCGCAACAGCGGCCCTTCTCCT TC-3'.
Expression of wild type and mutant hPDE5A1 GAF constructs. Sf9 cells (BD Pharmingen) were cotransfected with BaculoGold linear baculovirus DNA (BD Pharmingen) and one of the hPDE5A1 constructs in the pAcHLT-A baculovirus expression vector by the calcium phosphate method according to the protocol from BD Pharmingen. At 5 days post-infection, the cotransfection supernatant was collected, amplified three times in Sf9 cells, and then used directly as virus stock for expression without additional purification of recombinant viruses. Sf9 cells grown at 27 °C in complete Grace's insect medium with 10% fetal bovine serum and 10 µg/ml gentamicin (Sigma) in T-175 flasks (Corning) were typically infected with 10-100 µl of viral stock/flask. The optimum volume of viral stock used per T-175 flask was experimentally determined for each construct. The Sf9 cell pellet was harvested at 72-96 h post-infection.
Purification of hPDE5A1 holoenzyme and GAF constructs. The Sf9 cell pellet for each T-175 flask (~2 x 10 7 cells) was resuspended in 3 ml of ice-cold lysis buffer (20 mM Tris-HCl, pH 8, 100 mM NaCl), containing protease inhibitor mixture (Complete TM ; Roche Molecular Biochemicals) at the amount per volume recommended by the manufacturer. Cell suspension was homogenized in 10-to 20-ml aliquots on ice by 2 x 6-s bursts in an Ultra Turrex microhomogenizer (Tekmar) with a 20-s recovery between bursts and then centrifuged at 10,000 rpm in a Beckman JA-20 rotor for 20 min at 4 °C. The supernatant was loaded onto a Ni-NTA magnetic agarose (Qiagen) column (1 x 2 cm) equilibrated with lysis buffer. The supernatant volume varied depending on number of T-175 flasks infected. The column was washed with 100 ml of lysis buffer followed by sequential washes with lysis buffer containing a stepwise gradient of imidazole from 0.8 to 20 mM. Lysis buffer containing 100 mM imidazole was then allowed to soak into the Ni-NTA resin. The column was incubated for 2 h at 4 °C before ten 1-ml elutions were collected. Elutions containing proteins were pooled and dialyzed versus 2000 volumes of ice-cold 10 mM potassium phosphate, pH 6.8, 1 mM EDTA, and 25 mM β-mercaptoethanol (KPEM). All purification steps were done at 4 °C, and proteins were flashfrozen in KPEM plus 150 mM NaCl and 10% sucrose and stored at -70 °C. Prior to use in cGMPbinding and phosphorylation assays, proteins were dialyzed versus 50 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 150 mM NaCl.
Gel electrophoresis and western blot of hPDE5A1 constructs. The purity and integrity of proteins were assessed using SDS-PAGE followed by western blot or Coomassie blue staining. Proteins were boiled for 4 min in the presence of 10% SDS, 2 M β-mercaptoethanol, and 0.1% bromphenol blue and subjected to 12% SDSpolyacrylamide gel electrophoresis, and then visualized by Coomassie Brilliant Blue staining or western blot. For western blot, gels were transferred to polyvinylidene difluoride membrane (Millipore). Primary antibody was a rabbit polyclonal anti-PDE5, and secondary antibody was goat anti-rabbit horseradish peroxidase (BioSource International). The blot was developed using ECL chemiluminescence kit (Amersham Biosciences). For native gel electrophoresis (no SDS), two protocols were used. For studies of PDE5 holoenzyme, isolated GAF a and isolated GAF b constructs, protein samples were combined with sample buffer and loaded into wells of pre-cast 7.5% Tris-HCl acrylamide gels (Bio-Rad). Electrophoresis was performed in 25 mM Tris, 192 mM glycine running buffer, pH 8.3, and electrophoresis proceeded for 40 min at constant voltage (250 V) at room temperature according to the manufacturer's instructions. For studies of GAF b, the native gel was prepared as described previously (45) Determination of Stokes radius. Purified proteins (~5-70 µg) were combined with two internal standards, catalase (2 mg) and cytochrome c (2 mg), in a volume of 280 µl and loaded onto a Sephacryl S-200 gel filtration column (0.9 x 35 cm) equilibrated in KPEM and 150 mM NaCl at 4 °C. The column was eluted with the same buffer, and fractions (0.5 ml) were collected. To determine the elution position of the protein, 15 µl of each fraction was applied to a 12% gel for SDS-PAGE followed by silver staining (mutant 8) or western blotting of fractions with a rabbit polyclonal antibody directed toward PDE5 (mutants 1-5) or mouse monoclonal antibody directed toward Histag (mutants 7 and 8) (Amersham Biosciences). The second antibody was goat anti-rabbit or goat antimouse horseradish-peroxidase (BioSource International). Membranes were incubated with ECL reagents and then exposed to X-ray film for 2-10 s, conditions under which each exposure to the film does not reach saturation. Resultant films were scanned and quantified using METAMORPH software (Universal Imaging, Media, PA). The quantified protein bands were plotted using the intensity of the band in the peak fraction as 100% and quantifying the amount of the protein in surrounding fractions as percentage of that in the peak tube. Elution positions for those proteins containing the C domain (mutants 9 and 10) were determined using the PDE assay. Catalase and cytochrome c were located by absorbance at 280 nm. The column was standardized with protein standards of known Stokes radii: cytochrome c (16.6 Å), PKA C subunit (27 Å), ovalbumin (29 Å), bovine serum albumin (35 Å), PKGΙ-α (50 Å) and catalase (52 Å Determination of sedimentation coefficient. Purified proteins (~3-30 µg) were combined with two internal standards, crystalline catalase (2 mg), and cytochrome c (2 mg) in a volume of 200 µl in KPEM/150 mM NaCl and applied to a 13-ml linear 5-20% sucrose gradient containing KPEM/150 mM NaCl. The gradients were centrifuged at 31,000 rpm in a Beckman SW 41 rotor for 21 h at 4 °C, and fractions (0.5 ml) were collected from the bottom of the tubes. Catalase and cyctochrome c have sedimentation coefficients of 11.3 S and 1.86 S respectively, and were located by absorbance at 280 nm. The proteins of known s 20,w : cytochrome c (1.86 S), PKA C subunit (3.14 S), ovalbumin (3.5 S), bovine serum albumin (4.6 S), PKGΙ-α (7.0 S) and catalase (11.3 S) were centrifuged using the same conditions and used as standards. Values for sedimentation coefficients shown in Table 1 were obtained from this standard curve. To locate the peak of protein for each construct, SDS-PAGE followed by silver staining or immunoblotting of fractions and protein quantification were performed as described above. The sedimentation coefficient of each protein was then determined by the distance migrated into the gradients as compared with the standards. The molecular weight of each protein was calculated using the experimentally determined Stokes radius and sedimentation coefficient according to the method of Siegel and Monty (53) using the equation:
Eq.2 where N is Avogadro's number; n is the viscosity of medium, assumed to be 1; a is the Stokes radius; s is the sedimentation coefficient; ρ is the density of the medium, assumed to be 1; and ν is the partial specific volume, assumed to be 0.725 ml/g. Predicted Mr based on AA composition and Mr of the proteins based on the Siegel and Monty method were used to assess if each recombinant protein was monomeric or dimeric.
cGMP-binding activity. To measure cGMP binding, Millipore filtration and Sephadex G-25 gel filtration chromatography were used. The Millipore filter binding assays were conducted in a total volume of 50 µl reaction mixture that contained 40 mM MOPS, pH 7.5, 0.2 mg/ml bovine serum albumin, 0.2 mM sildenafil, 30 mM DLdithiothreitol (DTT), and various concentrations (0.001-5 µM) of [ 3 H]cGMP as indicated. The purified proteins (15 nM for holoenzyme, isolated R domain, 20 nM for GAF a) were pre-incubated 1 h at 4 °C in 30 mM DTT, and then used for the cGMP-binding assay. The reaction was initiated by addition of protein. After incubation for 1 h at 4 °C, 1 ml of cold KP buffer (10 mM potassium phosphate, pH 6.8) was added to each sample, and samples were filtered immediately onto premoistened Millipore HAWP filters (pore size 0.45 µm), which were then washed with 2 ml of cold KP buffer two times. Filters were then dried and counted using non-aqueous Ready Safe scintillation cocktail (Beckman). The bound protein counts were corrected by subtraction of nonspecific binding (+1 mM unlabeled cGMP). Blanks containing no protein were run for each concentration of The Sephadex G-25 gel filtration studies of cGMP binding were performed as follows: binding reactions were conducted as described above for 1 hr at 4 °C in a volume of 100 µl reaction mixture, and then each binding reaction mixture was loaded onto individual Sephadex G-25 columns (0.9 x 14 cm) equilibrated in KPM buffer at 4 °C. The column was rapidly eluted with the same buffer, and fractions (0.5 ml) were collected. PDE and PKG assays. PDE activity was determined by a modified assay (54) as described previously (55) using 0.001-20 µM (for experiments to determine K m ) or 0.4 µM (for experiments to locate the elution position of proteins) [ 3 H]cGMP as substrate for 10 min in a volume of 100 µl reaction mixture containing 50 mM Tris/HCl, pH 7.5, 10 mM MgCl 2 , 0.3 mg/ml bovine serum albumin. PKG activity was determined in the presence of 2 µM cGMP as described previously (55) .
[ 3 H]vardenafil membrane filtration-binding assay.
The [
3 H]vardenafil binding assay was conducted in a reaction mixture that contained 10 mM potassium phosphate, pH 6.8, and 25 mM β-mercaptoethanol, 0.2 mg/ml histone IIA-S and various concentrations of cGMP (0-500 µM). The binding reaction was initiated by addition of 0.07 nM of either PDE5 holoenzyme or a PDE5 construct containing GAF b plus C domain (mutant 10: T322-N875). After incubation for 45 min at 4 °C, 1 ml of cold KP buffer (10 mM potassium phosphate, pH 6.8) containing 0.1% Triton X-100 was added to each sample. Samples were filtered onto pre-moistened Millipore HAWP filters, and then washed, dried and counted as described previously (50) .
Preparation of isolated phospho-PDE5 proteins. PDE5 holoenzyme, isolated PDE5 R domain (mutant 1) and isolated GAF a (mutant 4) were phosphorylated using bovine catalytic subunit (C subunit) of PKA that had been purified to apparent homogeneity as described previously (56) . For experiments to determine the rate and cGMP dependence of phosphorylation 0.5 µM PDE5 holoenzyme, isolated PDE5 R domain or mutant containing only the isolated GAF a was added to a mixture containing the PKA C subunit (13 nM), 150 µM vardenafil, 20 mM magnesium acetate, 0.1 mM ATP (with addition of trace [
32 P]ATP), 10 mM potassium phosphate, pH 6.8, 0.1 M NaCl, and in absence or presence of 50 µM cGMP at 30 ºC. At varying times, aliquots of the reaction mixture were removed for SDS-PAGE analysis as described below, followed by autoradiography. Alternatively, aliquots of the reaction mixture were spotted onto phosphocellulose paper (P81), washed four times in 0.5% phosphoric acid, dried, and counted. For experiments to prepare quantitatively phosphorylated proteins, aliquots of R domain (mutant 1) and GAF a (mutant 4) were phosphorylated in the absence of cGMP using high concentration of C subunit (400 nM), nonradiolabeled ATP (2 mM) and magnesium acetate (10 mM) for 2 h at 30 ºC.
Determination of protein concentration. Protein concentration was determined by the method of Bradford using staining reagent from Bio-Rad and bovine serum albumin fraction V (Sigma) as standard.
Materials. 
Results:
Expression and purification of hPDE5A1 holoenzyme and GAF domain mutants. The structural features that provide for many of the functional features of the PDE5 R domain were defined by creating and characterizing the biochemical and biophysical properties of a collection of 10 recombinant His-tagged human PDE5A1 (hPDE5A1) R domain mutants (Fig. 1A) containing different combinations of the respective GAF a and b modules and their flanking regions. All mutants were expressed using the baculovirus/Sf9 cell expression system and detected on SDS-PAGE followed by western blot using a polyclonal PDE5-specific antibody. The estimated molecular mass of each of the respective bands on SDS-PAGE correlated well with that predicted based on the AA composition for each construct (Fig. 1B, Table 1 ). Protein yields varied somewhat among the constructs (100-1800 µg/liter infected cell media). All proteins were at least partially soluble and purified to near homogeneity (80-99% purity) (Fig.  1B ) using nickel-affinity chromatography as described in "Experimental Procedures". The constructs included: the recombinant human PDE5A1 holoenzyme (HE: M1-N875), full-length R domain (mutant 1: M1-E539), N-terminally truncated R domain construct containing both GAFs a and b and the phosphorylation site of Ser 102 (mutant 2: V46-E539), a collection of constructs containing the isolated GAF a and its respective flanking regions (mutant 3: M1-D403, mutant 4: M1-E321, mutant 5: V46-D403, mutant 6: V156-Q331, mutant 7: V156-D403), an isolated GAF b construct containing the respective flanking regions (mutant 8: T322-E539) and two constructs containing GAF b conjoined with the C domain (mutant 9: E420-N875, mutant 10: T322-N875). Mutant 9 lacked the 98 AA sequence between GAFs a and b, whereas mutant 10 included this sequence. The recombinant hPDE5A1 holoenzyme exhibited functional and structural properties that compared well to those previously reported for native and non-His-tagged recombinant bovine PDE5 (38, 57, 58) . The cGMP kinetic values for the recombinant hPDE5A1 used in the studies reported herein were as follows: K m = 3 ± 0.5 µM, V max = 1.0 ± 0.2 µmol/min/mg, and k cat (substrate turnover rate per mole of monomeric PDE) = 1.7 ± 0.2 sec -1 . Physical properties of PDE5A1 regulatory domain mutants. The quaternary structure for each mutant shown in Fig. 1A was determined according to the method of Siegel and Monty as described in "Experimental Procedures" (53) .
a. Physical properties of constructs containing both GAFs a and b. As shown in Fig. 2A , the gel filtration elution position of the isolated full-length R domain (mutant 1: GAF a/b) was similar to that of the internal standard catalase, and its Stokes radius was determined to be 55 Å. By sucrose density gradient centrifugation, the R domain (mutant 1) sedimented between the two internal standards, catalase and cytochrome c (Fig. 3A) , and its calculated sedimentation coefficient was 5.5 S. Based on these values, the calculated molecular mass of full length R domain (mutant 1: GAF a/b) was 125 kDa (Table 1) ; this value was approximately twice that of the predicted molecular mass of a monomer of this construct (63.5 kDa) based on AA composition, indicating that this construct is dimeric. To investigate the effect of the N-terminal 45 AA of the R domain, mutant 2 (V46-E539) containing both GAFs (a/b) was also analyzed. The Stokes radius and sedimentation coefficient values for this mutant were 52 Å and 6.1 S, respectively (Table 1) , and its calculated molecular mass was 131 kDa, consistent with a dimeric structure. These results validated the result found with mutant 1 and indicated that the Nterminal 45 AA segment does not measurably impact dimerization in constructs containing both GAF modules.
b. Physical properties of constructs containing only GAF a or GAF b. In order to more closely examine the potential role of each GAF and its surrounding sequences in dimerization, the quaternary structures of four mutants (mutants 3-5 and 7) containing isolated GAF a with various combinations of flanking regions and three mutants containing GAF b alone with various flanking regions (mutant 8) or GAF b conjoined with the C domain (mutants 9 and 10) were characterized. All four constructs containing only GAF a were dimers, and all three constructs containing only GAF b could also form dimers (Table 1) . On gel filtration chromatography, mutant 3 (M1-D403) containing GAF a, the complete N-terminal region of PDE5, and the short segment of sequence between GAFs a and b had a Stokes radius of 59.8 Å. Its sedimentation coefficient was 4.3 S. The calculated molecular mass for this mutant was 106 kDa, consistent with a dimeric structure (Table 1) . Both mutants 4 (M1-E321) and 5 (V46-D403) containing GAF a and a complete or truncated N-terminal region, respectively, were dimers based on their calculated molecular masses (Figs. 2B and 3B, Table 1 ). Based on similar analysis, the quaternary structure of the shortest mutant containing the isolated GAF a (mutant 7: V156-D403) was dimeric (Table 1) . Compared to constructs containing the first 45 AA, constructs containing only GAF a, but lacking the N-terminal 45 AA, migrated as somewhat broader peaks on gel filtration chromatography and on sucrose density centrifugation (data not shown). This suggested that the N-terminal 45 AA of PDE5 may contribute to stabilizing the R domain quaternary structure at least when only GAF a is present. The protein concentration of the peak fractions for mutants 3 and 4 following the respective Sephacryl S-200 chromatographies was determined by the Bradford method to be ~30 nM, indicating that the minimum K D for formation of a stable dimer in GAF a constructs (mutants 3 and 4) is less than 30 nM.
Mutant 8 (T322-E539) containing the sequence between GAFs a and b as well as the C-terminal flanking region to GAF b had a Stokes radius of 33 Å (Fig. 2C, Table 1 ) and a sedimentation coefficient of 4.3 S (Fig. 3C) . The calculated molecular mass of this mutant (59 kDa) compared to that predicted from the AA composition (28.3 kDa ), indicating that it is also a dimer (Table 1) . Protein products of constructs of either GAF a (E238-E321) or GAF b (E420-E510), without their flanking regions were apparently unstable; despite reasonably good expression of appropriately sized proteins in the Sf9 lysates (as detected by western blot), very little of these mutants was recovered following the Ni + -affinity chromatography. This was observed for at least 3 preparations of each mutant despite the presence of protease inhibitors in the lysis buffer. To further examine the role of GAF b in mediating PDE5 dimerization, and to determine if the short segment between GAF a and b contributes to stability of the dimerization mediated by GAF b, the quaternary structure of each of two constructs containing GAF b and extending through the C domain (mutant 9: E420-N875 and mutant 10:T322-N875) were examined. The catalytic activity of each of these mutants was used to detect the proteins in order to calculate the Stokes radii and sedimentation coefficients. The K m and k cat values for mutant 9 were 1.1 µM and 0.9 sec -1 , respectively, and those for mutant 10 were 1.3 µM and 0.93 sec -1 , respectively. The K m value for each of these constructs had 2-to 3-fold higher affinity than that of holoenzyme (K m and k cat values of 3.0 µM and 1.7 sec -1 respectively). This slight increase in affinity for cGMP mimicked the effect of phosphorylation or cGMP binding on the K m value. Whether this is a meaningful difference is not clear. Removal of GAF a and its potentially negative influence when not occupied by cGMP might account for these subtle differences.
Mutant 9 lacked the short segment between GAFs a and b (E321-D403), while mutant 10 contained this sequence. On gel filtration, mutants 9 and 10 had Stokes radii of 59.6 Å, and 56 Å, respectively (Fig. 4, Table 1 ). Because the Stokes radius reflects shape as well as size, it was possible that mutant 9, which lacked the short segments of sequence between the GAFs, existed in a more extended conformation compared with mutant 10. On sucrose density gradient centrifugation, the sedimentation coefficients were 4.1 S for mutant 9 and 5.0 S for mutant 10 . The values for the calculated molecular mass for each of these constructs (mutants 9 and 10) were 102 and 116 kDa, respectively, compared to the molecular mass predicted from AA composition, i.e., 55.2 kDa (mutant 9) and 64.2 kDa (mutant 10) (Table 1 ). Protein concentration of the peak fraction for each mutant following the respective Sephacryl S-200 chromatography was ~20 pM, indicating that the K D for dimer formation by two GAF b modules is <20 pM. The presence of the functional C domain in mutants 9 and 10 was exploited in order to determine the affinity with which GAF b and/or the GAF b plus the sequence between the two GAFs provides for dimerization. The highly sensitive PDE catalytic activity allows for extensive dilution of the proteins for such analyses, and molar concentration of the respective proteins can be calculated based on catalytic rate. Early fractions from each peak on the Sephacryl S-200 chromatography that elute in a position consistent with a dimeric structure were used for the experiment. Protein concentration in each of these fractions was ~20 pM. Each fraction was individually rechromatographed on Sephacryl S-200 gel filtration column, and the protein was located by measuring catalytic activity. Following rechromatography, the elution position of mutant 9 was quantitatively shifted to a single peak that eluted between the two internal standards and had a Stokes radius of 35.6 Å, consistent with a monomeric structure (Fig. 4A) . In the peak fraction of mutant 9, the protein concentration following rechromatography was ~1 pM. This indicated that the K D value for dimerization between two GAF b modules is between 1-20 pM. In contrast, the elution position of mutant 10 following rechromatography on Sephacryl S-200 and similar dilution (peak fraction protein concentration of 1 pM) was essentially unchanged; this result was consistent with mutant 10 remaining a dimer (Fig.  4B Table 2 ). These values for PDE5 holoenzyme and the isolated R domain constructs were similar to those reported earlier for recombinant PDE5, native PDE5, and the GST fusion R domain construct (27, (59) (60) (61) . Cyclic GMPbinding affinities of proteins containing only GAF a (K D = 35 ± 5 and 28 ± 3 nM for mutants 4 and 5, respectively) were ∼3-fold higher than that of isolated R domain containing both GAFs and ~6-fold higher than that of holoenzyme (Fig. 5,Table 2 32 P]phospho-forms of the proteins were prepared and filtered by the same protocol. By this method, the recovery of protein in the filtration assay for full-length enzyme or the isolated GAF a construct (mutant 4) was 75% and 45%, respectively, and values were corrected accordingly. Stoichiometry of cGMP-binding was 0.75 ± 0.08 mol/mol of subunit (n = 10), 0.45 ± 0.06 mol/mol of subunit (n = 12), and 0.17 ± 0.03 mol/mol of subunit (n = 8) ( Table 2) for full-length recombinant PDE5, isolated R domain (mutant 1), and isolated GAF a (mutant 4), respectively.
The second approach for determining cGMPbinding stoichiometry of these constructs employed Sephadex G-25 gel filtration (Amersham Biosciences). Stoichiometry of cGMP-binding for holoenzyme, isolated R domain (mutant 1:GAF a/b) and mutants containing only GAF a (mutants 4 and 5) using this procedure were 0.75, 0.55 and 0.20, 0.21 mol/mol of subunit, respectively (n = 2 for each), which agreed well with the values obtained using Millipore filtration (Table 2) . A 176 AA segment (mutant 6: V156-Q331) containing isolated GAF a was sufficient for cGMP binding with a stoichiometry comparable to that of other mutants containing only GAF a (mutants 4 and 5). This indicates that structural features contained within these 176 AA are sufficient to provide for a stable and functional GAF domain.
The lower stoichiometry of cGMP-binding for the isolated PDE5 GAF a constructs suggested a possible role for PDE5 GAF b in stabilization of GAF a structure and function. However, the possibility that the conditions used in the two cGMP-binding assays were not optimal for GAF a or that GAF b may bind cGMP under certain circumstances could not be excluded.
Four methods were used in an effort to detect cGMP binding by mutants containing only GAF b. Using either Millipore filtration or the Sephadex G-25 methods described above, no significant cGMPbinding was detected for PDE5 mutants containing only GAF b (mutants 8-10). However, a low cGMP-binding affinity by GAF b might compromise detection by these methods. In attempt to detect even low-affinity cGMP binding, the effect of cGMP to alter migration of the mutant proteins containing only GAF b on native gel electrophoresis as described in "Experimental Procedures" was examined. In contrast to the effect of cGMP to substantially slow electrophoretic mobility of PDE5 holoenzyme, isolated PDE5 R domain (mutant 1), and a mutant containing only GAF a (mutant 4), high concentration of cGMP (10 mM) did not slow the migration of a mutant containing only GAF b (mutant 8) (data not shown). The fourth approach employed the [ 3 H]inhibitorbinding assay that we previously reported (50, 51) . In PDE5 holoenzyme, allosteric cGMP binding increases the catalytic site binding affinity for sildenafil, tadalafil, and vardenafil (50, 51) . However, in contrast to the effect seen with PDE5 holoenzyme in a head-to-head comparison, cGMP (0-500 µM) did not alter binding of 
c. Kinetics of [ 3 H]cGMP dissociation/exchange of the isolated PDE5 GAF a are biphasic. The characteristics of the exchange/dissociation kinetics of [
3 H]cGMP bound to PDE5 allosteric sites were determined in a head-to-head comparison of PDE5 holoenzyme, isolated R domain (mutant 1: GAF a/b) and a mutant containing only GAF a (mutant 5) as described in "Experimental Procedures".
The pattern of cGMP dissociation/exchange kinetics from hPDE5 holoenzyme is curvilinear, which is a similar finding to that previously reported for bovine PDE5 (60) (data not shown). Patterns for cGMP dissociation/exchange from isolated R domain (mutant 1) or isolated GAF a (mutant 4) also revealed at least two rate components in each protein (Fig. 6 ). The fast component in either the holoenzyme (not shown) or the isolated R domain required ~100 min for completion, while the slower component required ~900 min. When the line of the slower component was extrapolated to the y-axis, the calculated percentage of the two components among the three proteins was quite similar. Recombinant hPDE5 holoenzyme exhibited 70% high affinity (slow) and 30% low affinity (fast) components, a pattern that differed somewhat from the more equal distribution reported earlier (59) (60) (61) . The proportion of the two kinetic rates was stable in different buffers (MOPS, and potassium phosphate) and at different pH conditions (pH 6.8 and 7.5). Under the conditions used here, the t 1/2 value for the lower affinity component (39.0 ± 5 min) for PDE5 holoenzyme was ~10-times faster than that for the higher affinity component (t 1/2 of 465 ± 25 min) (data not shown). The pattern for [ 3 H]cGMP dissociation/exchange from the isolated R domain containing both GAFs a and b (mutant 1) contained 68% high-affinity and 32% low-affinity components with the t 1/2 of the low-affinity component (42 ± 5 min) being ~10 faster than that for the high-affinity component (439 ± 25 min). The dissociation behavior of [ 3 H]cGMP from mutant 4 which contained only GAF a, exhibited 78% high-affinity and 22% low-affinity components, which was similar to the pattern for the other two proteins. However, t 1/2 value for the low-affinity component (110 ± 5 min) was ~3 times slower than that in the isolated R domain or holoenzyme, whereas dissociation/exchange from the high-affinity component was only slightly slower (t 1/2 of 530 ± 38 min).
PDE5A1 R domain and isolated GAF a bind cGMP with >100 fold higher affinity than that for cAMP.
Competition analysis was employed to analyze the cN-selectivity of the full length R domain (mutant 1: GAFs a/b) and two constructs containing isolated GAF a alone (mutants 4 and 5) (Fig. 7) . Proteins were incubated with [ 3 H]cGMP (0.23 µM) in the absence or presence of increasing concentrations of either cAMP or cGMP. Fulllength R domain exhibited a 100-fold specificity for cGMP over cAMP. Cyclic AMP competed with cGMP binding to the isolated PDE5 R domain (GAFs a/b) with an IC 50 of 36 µM (Fig. 7, Table 3 was compared using PDE5 holoenzyme, isolated R domain (mutant 1: GAF a/b) and isolated GAF a (mutant 4:GAF a) (Fig. 8) . In contrast to the cGMP stimulation of phosphorylation of holoenzyme or isolated R domain, phosphorylation by PKA C subunit of a mutant containing the sequence extending from the N-terminus through GAF a was not regulated by allosteric cGMP binding (Fig. 8) . Under these conditions, using low PKA C subunit concentration (12 nM), the stoichiometries of phosphorylation of isolated PDE5 R domain and mutant 4 containing the isolated GAF a domain at the final time point were 0.25 ± 0.05 and 0.22 ± 0.02 mol of phosphate per subunit of protein, respectively. Radiolabel was shown to be associated only with serine phosphate.
cGMP binding, but not phosphorylation, induces an apparent conformational change in a mutant containing GAF a. The effects of cGMP binding and of phosphorylation on the migration of a mutant extending from the N-terminus through GAF a (mutant 4) or PDE5 holoenzyme on native PAGE (no SDS) were compared (Fig. 9) . Unphospho-and phospho-forms of mutant 4 containing GAF a and PDE5 holoenzyme were prepared using nonradiolabeled ATP according to the protocol for quantitative phosphorylation described under "Experimental Procedures". The stoichiometry of phosphorylation of both proteins under these conditions using high concentration of PKA C subunit (400 nM) was ~0. . Since cGMP migrates rapidly toward the anode and is removed quickly from the environs of the protein, high concentration of cGMP was used in the preincubation in an attempt to maximize the likelihood that cGMP would remain bound to the proteins. Phosphorylation of PDE5 holoenzyme also slows migration of the protein on native PAGE (Fig. 9A, Lane 3 ), but phosphorylation of mutant 4, which contains the sequence from the N-terminus through GAF a, did not measurably slow the migration (Fig. 9B, Lane 3) . However, when either protein was phosphorylated in the presence of cGMP (15 mM), migration of the proteins on the gel was slowed similarly to the effect of cGMP binding alone on migration. The stoichiometry of phosphorylation was the same in the presence and absence of cGMP.
Discussion:
The roles of the two GAFs and surrounding sequences in the PDE5 R domain were systematically investigated by creating and characterizing the physical and biochemical properties of a collection of truncation mutants containing one or both GAFs. The important roles that were established previously for phosphorylation and allosteric cGMP-binding in modulating function of PDE5 holoenzyme provided a compelling need for molecular analysis of the structural characteristics and functional roles of the R domain.
Dimerization of hPDE5A1 may involve multiple sequences including GAF a and GAF b. Almost all known mammalian PDEs studied exist as dimers or oligomers, and characterization of dimerization interactions have been reported for PDEs 2, 4, and 6 (14, 63, 64) . In the closely related cGMP-binding PDEs, i.e., PDEs 2, 5, and 6, dimerization occurs through interactions in the N-terminal R domain, and one or both GAF domains in these proteins have been implicated in dimerization. In the X-ray crystal structure of the isolated R domain of PDE2, the monomers align in a head-to-head arrangement in which the GAF a modules in the two monomers dimerize (14) . The X-ray crystal structure of the S. cerevisiae YKG9 GAF domain reveals that it is also dimeric (42), but the contacts in PDE2 GAF a differ from those in the YKG9 GAF (42) . The more Cterminal GAF b modules in the two monomers of PDE2 are well separated in space. For other GAFcontaining PDEs, dimerization contacts are not known. In PDE6 α and β subunits, the N-terminal part of GAF a is the key module for determination of dimerization specificity between the heterologous catalytic subunits, thereby disallowing homodimerization (63) . However, another set of interactions involving AA at the start of the helix connecting GAFs a and b may also be involved in PDE6 dimerization (63) . Although PDE4 is not a GAF-containing PDE, interactions involving an Nterminally located module of similar size to GAFs (UCR1/UCR2) contribute importantly to its oligomerization (64) . In combination, these results suggest that dimerization of many PDEs involves contacts within the N-terminal portion of the protein. However, dimerization interfaces have also been revealed for the isolated C domains of PDEs 4A, 4D, and 9, but not of PDE5 (40, 41, 65, 66) .
In the present studies, we provide evidence that both isolated GAF a and GAF b modules in PDE5A1 contain structural features that have the potential to provide for dimerization of the enzyme. Both GAFs a and b from PDE5A can homodimerize with strong affinity even in the presence of high concentrations of other proteins and at nearly physiological salt concentration. The K D for homodimerization of a construct containing GAF a is < 30 nM and between 1-20 pM for a construct containing GAF b. This is the first estimate of the affinity of protein-protein interactions reported for dimerization of a GAF in any protein. Dimerization contacts are provided within a 248 AA segment of sequence containing GAF a and the N-terminal 45 AA may contribute to stabilization of the protein structure. Contacts within a segment of 218 AA containing GAF b provide for dimerization. If both GAFs are not involved in PDE5 dimerization, there must be powerful constraints to block these interactions since the GAFs containing such highaffinity binding potential are closely juxtaposed within the dimer. Furthermore, given the capacity of each GAF to form stable dimers, it raises the question as to whether dimerization in PDE5 holoenzyme exclusively occurs between two GAF a modules or two GAF b modules; heterodimerization may occur in some instances. Questions generated by our results apply not only to PDE5 but to other GAF-containing PDEs and will require additional structural information to resolve these issues.
Our results indicate that a short segment of sequence between GAFs a and b can contribute to stabilization of the PDE5 dimer. The basis for this effect is not known, but a leucine zipper motif (Ile 312 -X 6 -Leu 318 X 6 -Glu 324 X 6 -Leu 331 -X 6 -Ile 337 -X 6 -Leu 344 -X 6 -Ile 351 ) located in the segment of sequence between the GAFs might contribute. Disruption of this motif in PDE5 holoenzyme by site-directed mutagenesis does not produce monomerization (39) . However, the high affinity of dimerization imparted by either GAF a or GAF b might mask a weakened interaction in this motif. Other contacts such as a disulfide bond might also provide the additional stabilizing force of the intervening sequence. Within the quaternary structure of PDE5 holoenzyme, just one of these regions may be involved in dimerization. Alternatively, different conformations of PDE5 could utilize different complements of these three components for dimerization contacts. Further experiments are required to confirm the possibility of impact of dimerization on PDE5 structural or functional stabilization, e.g., affinity for PDE5 inhibitors, and to fully define the dimerization contacts.
Mutants containing GAF a , but not GAF b, bind cGMP with high affinity and high specificity. By stoichiometric determinations, apparently one cGMP is bound per monomer of PDEs 2, 5, and 6, but the cGMP-binding properties of these PDEs are kinetically heterogeneous (12, 20, 59, 60, (67) (68) (69) (70) . Several lines of evidence indicate that PDE5 holoenzyme and its isolated R domain exhibit multiple conformations that relate to alterations in catalytic and/or allosteric cGMP-binding activity (14, 27, 45, 50, 51) . The resolution of different conformers of PDE5 and isolated R domain on native PAGE, the biphasic kinetics of cGMP dissociation from PDE5 holoenzyme or isolated R domain, and the biphasic dissociation characteristics of inhibitors from PDE5 catalytic site are compelling arguments for conformational/functional heterogeneity.
The heterogeneity of allosteric cGMP-binding could be derived from differences in the structure/function of a single population of GAFs (either GAF a or b), from different kinetics associated with cGMP-binding to both GAF a and b within a single PDE monomer or dimer, or from PDE molecules in different conformations. Conversion of the curvilinear pattern of cGMP dissociation/exchange kinetics to a single rate following phosphorylation of Ser 102 provides convincing evidence for reversible interconversion between two conformers (27) . A PDE5 construct containing only GAF a was reported to exhibit a single high-affinity cGMP-binding site (20) . Results from that study and those from earlier reports are consistent with a potential role for GAF b in contributing the low-affinity cGMP-binding component in PDE5 (60, 61, 68) . However, in the current report, we demonstrate that cGMP binding by constructs containing GAF a, but not GAF b, can account for the biphasic pattern of cGMP dissociation/exchange observed in holoenzyme and isolated R domain.
In earlier reports, the proportion of high-affinity and low-affinity cGMP-binding components in PDE5 was approximately equal, but in the head-tohead comparisons of the PDE5 holoenzyme, isolated PDE5 R domain, and GAF a mutants reported herein, the high-affinity and low-affinity components of cGMP binding account for ~70% and ~30%, respectively. These slight, but clear, differences in the distribution of cGMP binding among two kinetic species compared with those from earlier studies suggest that the distribution of two conformations of these proteins varies among preparations. The conformers appear to be relatively stable under different conditions of pH and buffer.
We have shown that a mutant containing the GAF a domain in a sequence of 176 AA binds cGMP. When this sequence is aligned with that of PDE2 GAF b, it overlaps almost precisely with the short segment of sequence from PDE2 GAF b that also binds cGMP with high affinity (52) . This shared retention of function between two cGMP-binding GAFs strongly supports the interpretation that elements within these sequences are adequate for structural stability and biochemical function.
The GAF-containing R domains in PDEs 2, 5 and 6 are highly selective for cGMP over cAMP. PDE2 holoenzyme exhibits a ~10-fold higher affinity for cGMP (14, 52) compared to the >100-and 100,000-fold selectivity for cGMP over cAMP in PDE5 and PDE6C holoenzymes, respectively (57,) . According to the crystal structure of PDE2 GAF b, the AA that interact with the cN pyrimidine ring (D439, F438 and T488) were predicted to be major determinants of cGMP/cAMP specificity (14) . Mutation of these AA in PDE2 GAF b increases cAMP-binding affinity (~8 fold) but only slightly decreases cGMPbinding affinity (~2 fold) (52) . These AA are conserved in PDE5 GAF a, which shows highest sequence identity (48%) with the cGMP-binding GAF b of PDE2. However, cGMP-binding affinity by PDE5A GAF a is > 200-300-fold greater than that for cAMP indicating that PDE5 GAF a must contain additional features that provide for the higher cGMP selectivity. Among these AA in PDE2, only T488 is absolutely conserved in PDE6A GAF a and D439 is conserved in PDE6 GAF b.
No evidence could be found for cGMP binding by PDE5 GAF b, but the region containing this module and its flanking AA plays important roles in PDE5 function. First, this region appears to impact cGMP-binding properties of GAF a. The intrinsic cGMP-binding affinity in mutants containing only GAF a is ~3-fold greater than that of isolated R domain or holoenzyme. This indicates that the intrinsically high affinity provided by the AA sequence and structure of GAF a is diminished, i.e., autoinhibited, by other structures within the R domain. Since high affinity cGMP binding occurs in a construct extending from PDE5 N-terminus through GAF a, but lacking GAF b and its flanking regions, it can be inferred that autoinhibition is effected by a component(s) in the region of GAF b.
Autoinhibition of allosteric cGMP-binding affinity may occur in other PDEs since the cGMPbinding affinities of isolated PDE2A R domain and its isolated GAF b are also ~4-fold higher than that for holoenzyme (18, 52) . This feature is also conserved in PDEs of lower organisms; cAMP-and cGMP-binding affinities of an isolated TbPDE2B (a cAMP-specific PDE of T. brucei) GAF a are 3-and 35-fold higher than those of holoenzyme (23) . All these findings strongly support the hypothesis that the cN-binding affinity of GAF(s) can be reversibly suppressed, i.e., autoinhibited, by other components of these enzymes; in PDE5 this autoinhibition could occur by direct contacts with GAF b and/or its flanking sequences or could be elicited by conformational changes in GAF a resulting from structural changes in GAF b and its flanking sequences. The second potential impact of the GAF b region on cGMP binding by GAF a is demonstrated by the somewhat lower cGMPbinding stoichiometry in mutants containing only GAF a compared to that in the isolated R domain or holoenzyme. Whether cGMP binds to both GAFs in the GAF a homodimer is not known. The presence GAF b and its flanking regions in the R domain may induce structural changes that allow for cGMP binding in both GAF a sites. The third impact of this region in PDE5 function is regulation of the availability of Ser 102 for phosphorylation by cN-dependent protein kinases. While phosphorylation of Ser 102 is tightly substrateregulated by allosteric cGMP binding in both PDE5 holoenzyme and the isolated R domain, in a mutant containing the complete N-terminus through GAF a, phosphorylation proceeds equally well in the absence or presence of cGMP binding. The results suggest that in the absence of cGMP binding in GAF a, the sequence in the R domain containing GAF b and its flanking regions, i.e., T322-E539, provide the mechanism for sequestration of Ser 102 . Phosphorylation of Ser 102 within the full-length R domain increases cGMP-binding affinity and removal of the sequence containing GAF b and its flanking sequences from the R domain also increases the cGMP-binding affinity by GAF a. This effect on Ser 102 exposure could be due to direct interaction of Ser 102 with a site in or near GAF b that protects this AA from phosphorylation or to an indirect conformational constraint imposed by GAF b and its flanking sequences. This would also lead to the prediction that this contact may concomitantly decrease cGMP-binding affinity of GAF a. Recent evidence suggests that in some instances GAF b may also impact interaction of the catalytic site with PDE5 inhibitors (Blount et The abbreviations used are: PDE, 3′, 5′-cyclic nucleotide phosphodiesterase; cN, cyclic nucleotide; cGMP, cyclic guanosine 3′, 5′-monophosphate; cAMP, cyclic adenosine 3′, 5′-monophosphate; GAF, a protein motif conserved in mammalian cGMP-binding PDEs, Anabaena adenylyl cyclases, and Escherichia coli FhlA; PKA, cAMP-dependent protein kinase; R domain, regulatory domain; C domain: catalytic domain, PDE5A, cGMP-binding, cGMP-specific PDE; PDE2A, cGMP-stimulated PDE; DTT, dithiothreitol; KPEM, 10 mM potassium phosphate, pH 6.8, 1 mM EDTA, and 25 mM β-mercaptoethanol; AA, amino acid; IBMX, 3-isobutyl-1-methylxanthine. Fig. 1 . Constructs of isolated hPDE5A1 used in these studies. A: Schematic representation of constructs generated in this study containing different combinations of GAF domains and the phosphorylation site at Ser 102 . Mutants 1-5 contain the site for phosphorylation by PKG or PKA at Ser 102 (indicated by gray oval). The conserved region of the C domain is indicated by the gray box. B: Analysis of the purified isolated hPDE5A1 R domain mutants by SDS-PAGE as described in "Experimental Procedures". N-terminally Histagged proteins were expressed in Sf9 cells then purified to near homogeneity using nickel affinity chromatography as described in "Experimental Procedures". 3-10 µg of proteins were analyzed by 12% SDS-PAGE and stained with Coomassie blue. Molecular size is indicated on the left. Lanes M, 1-10 and HE contain low molecular weight markers, mutants 1-10 and holoenzyme, respectively. The western blots were performed using a PDE5-specific polyclonal antibody for mutants 1 and 4 or monoclonal His-antibody for mutant 8, as described under "Experimental Procedures". The protein bands visualized by western blot analysis were quantified and plotted using the intensity of the protein band in the peak fraction as 100% and quantifying the amount of the protein in surrounding fractions as a percentage of the amount in the peak fraction. Absorbance at 280 nm was used to determine the elution positions of catalase and cytochrome c as described under "Experimental Procedures". Results in these figures are representative of three experiments. were subjected to sucrose density gradient centrifugation (5-20%) as described under "Experimental Procedures". 2 mg of catalase and 2 mg of cytochrome c were included as internal standards. Following centrifugation, 0.5 ml fractions were collected. To locate the respective proteins, 10 µl aliquot of each fraction was loaded on a 12 % SDS-PAGE gel followed by western blot using a polyclonal PDE5-antibody for mutants 1 and 4 or a monoclonal His-antibody for mutant 8, as described under "Experimental Procedures". The resultant protein bands were quantified and plotted as described in Fig. 2 . Absorbance at 280 nm was used to determine the elution positions of catalase and cytochrome c. The results in these figures are representative of three experiments. Fractions (0.5 ml) were collected and assayed for PDE activity to determine elution position for each mutant. The molar concentration of the respective proteins was calculated based on the catalytic rate and determined to be ~20 pM for both mutants 9 and 10. Absorbance at 280 nm was used to determine the elution positions of catalase and cytochrome c. Aliquots (330 µl) of protein in early fractions from each peak (fractions 30 and 35 for mutants 9 and 10, respectively) on the Sephacryl S-200 chromatography that eluted in a position consistent with a dimeric structure were rechromatographed using a Sephacryl S-200 gel filtration column as described above. Protein concentration in the peak fraction for both mutants following rechromatography was ~1 pM. 3 H]cGMP was determined by the Millipore vacuum filtration method as described under "Experimental Procedures". One site binding curve fitting (Prism, Graphpad) was used to obtain K D values. In order to emphasize the difference between curves, the data points generated from the last four cGMP concentrations (3, 4, 5, and 6 µM) and used for the K D determination were removed. The data is representative of three experiments each performed in triplicate. Fig. 8 . Comparison of the effect of cGMP on the rate of phosphorylation of PDE5 holoenzyme, the isolated PDE5A1 R domain, and the isolated GAF a by PKA C subunit. Purified PDE5 holoenzyme, isolated R domain (mutant 1) and GAF a construct (mutant 4) were phosphorylated in presence of [ 32 P]ATP as described under "Experimental Procedures" using purified PKA C subunit (12 nM) in absence and presence of 50 µM cGMP. Aliquots of protein were removed at indicated time points, immediately combined with 2 mM EDTA and 10% SDS and 2 M 2β-mercaptoethanol, and boiled for 4 min. Samples were then subjected to 10% SDS-PAGE. Gels were silver stained (lower panel in each), dried, and analyzed by autoradiography. Gels are representative of five separate experiments. Fig. 9 . cGMP binding, but not phosphorylation, of a construct containing the N-terminus through GAF a is associated with an apparent conformational change. Purified PDE5 holoenzyme (panel A) and mutant 4 (panel B) were preincubated for 90 min at 30 °C in the absence of additions (control) or in the presence of cGMP (15 mM) (+cGMP). Aliquots of the samples were also incubated with C subunit (400 nM), magnesium acetate (10 mM) and ATP (2 mM) in the absence (phospho-protein) or presence of cGMP (15 mM) (+cGMP, phospho-protein). Protein samples were then subjected to 7.5 % native gel electrophoresis as described under "Experimental Procedures." Protein was detected using silver stain. Arrow indicates mobility of one band of bovine serum albumin (Sigma) used as native gel standard. The gel is representative of five separate experiments.
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